Following is info re Abagovomab. It and all monoclonal antibodies are a passive immunotherapy.
PRR's CVac is a dendritic cell cancer vaccine or a ACTIVE IMMUNOTHERAPY which is much stronger.
Also is the expert call with Dr Jonathan Berek he talks about the future of treatment and that there is leverage so if a antibody is approved for ovarian cancer(either Abagovomab or Avastin) then there is leverage to use it with CVac. It compliments the use and will actual encourage more use.
Listen to this opinion on
http://www.investorcalendar.com/IC/CEPage.asp?ID=163542
-----------------------------------------------------------
AbagovomabFrom Wikipedia, the free encyclopedia
Jump to: navigation, search
Abagovomab ?
Monoclonal antibody
Type Whole antibody
Source Mouse
Target (imitates CA-125)
Identifiers
CAS number 792921-10-9
ATC code None
Chemical data
Formula ?
Pharmacokinetic data
Bioavailability N/A
Excretion N/A
Therapeutic considerations
Pregnancy cat. N/A
Legal status under clinical development
Routes subcutaneous
Y(what is this?) (verify)
Abagovomab is a mouse anti-idiotype monoclonal antibody whose variable epitope mirrors a tumour antigen (CA-125) highly expressed in the epithelial ovarian cancer. Abagovomab does not bind directly to CA-125, but it works as a "surrogate" antigen, enabling the immune system to identify and attack tumour cells displaying the CA-125 protein. Through this, it is hoped that the body's immune system may be able to combat any remaining individual tumour cells and thus prevent recurrence of the disease.
Contents [hide]
1 Current status
2 Phase II
3 Ovarian cancer
4 Development
5 Further reading
6 External links
[edit] Current statusAbagovomab is currently under clinical development in patients with advanced ovarian cancer, as consolidation of the remission status obtained following surgery and standard platinum and taxane first line chemotherapy.
[edit] Phase IIIn a Phase II study on 119 patients with advanced ovarian cancer in which the standard therapies had already been ineffective, treatment with abagovomab led to a prolongation of survival time (23.4 months compared to 4.9 months) in those patients who responded to the vaccination, i.e. those in whom the formation of antibodies against the tumour was proven (almost 70 % of patients). The vaccine showed hardly any side effects in preliminary studies.
[edit] Ovarian cancerOvarian cancer is the most malignant tumour of the female reproductive organs. After endometrial cancer, it is the second most common genital tumour in women with approximately 9,000 women newly affected each year and, because of its aggressiveness, it has the highest mortality rate. This is due in part to the fact that there is no screening examination for early detection, and that the disease is therefore usually only discovered at an advanced stage, and in part to the tumour's tendency, although responding well to initial treatment, to recur again later.
In spite of initially successful treatment with surgery and chemotherapy, which forces back the tumour "completely", i.e. into no longer visible residues, there is a relapse of the disease (recurrence) in more than half the women affected. Today, no further therapy would be conducted in this situation as long as the disease did not occur again, i.e. clinical monitoring of the symptom-free patients as part of follow-up care is the current standard procedure. In this time-window of the patient?s history so called ?watch and wait? abagovomab is potentially capable of deferring or even preventing the occurrence of the relapse.
[edit] DevelopmentAbagovomab has been developed by the pharmaceutical company Menarini. A multicenter clinical trial, internationally known as MIMOSA (Monoclonal antibody Immunotherapy for Malignancies of the Ovary by Subcutaneous Abagovomab), in which Abagovomab will be administered as maintenance therapy (after first line therapy with surgery and chemotherapy), is ongoing in patients with ovarian cancer. Nine hundred women in whom the ovarian tumour was removed by surgery and standard chemotherapy with paclitaxel and carboplatin can be enrolled in the MIMOSA study, involving eight countries throughout the world (Germany, USA, Italy, Poland, Czech Republic, Spain, Hungary and Belgium) in more than 120 experienced clinical sites.
- Forums
- ASX - By Stock
- IMM
- the economist - cancer drug article 26/5/11
the economist - cancer drug article 26/5/11, page-2
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
40.0¢ |
Change
0.005(1.27%) |
Mkt cap ! $569.8M |
Open | High | Low | Value | Volume |
40.0¢ | 40.0¢ | 39.0¢ | $1.746M | 4.422M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 7395 | 39.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
40.5¢ | 94636 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 7395 | 0.395 |
11 | 507295 | 0.390 |
12 | 433222 | 0.385 |
21 | 656016 | 0.380 |
5 | 305455 | 0.375 |
Price($) | Vol. | No. |
---|---|---|
0.405 | 94636 | 3 |
0.410 | 250000 | 2 |
0.415 | 100000 | 1 |
0.420 | 47658 | 4 |
0.425 | 35972 | 2 |
Last trade - 16.10pm 19/06/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
P.HOTC
HotCopper
Don Currie, CEO
Don Currie
CEO
Previous Video
Next Video
SPONSORED BY The Market Online